With tremendous pride, enthusiasm and hope, I honored to share the Roadmap to Cure ALS. This was created from the brilliant minds of 87 international researchers, academics and advocates from industry and government who met each week of October 2020 in virtual workshops to discuss approaches and research deemed vital to cure ALS. This symposium was sponsored and led by the ALS CURE Project, Livermore Lab Foundation and Lawrence Livermore National Laboratory. We are hopeful that ALS research organizations and funding entities will utilize this roadmap to focus research efforts to optimize our path to a cure for this horrific disease.
Cases at Any
New Cases Each
the ALS community
and retinal scans
Cases at Any
New Cases Each
Road Map To A Cure
Following the passing of my dear wife Gretchen in May of 2018, I made good on a promise to her to work towards a cure for ALS so “nobody would have to suffer my (Gretchen’s) fate.” I have created a not-for-profit organization, known as the ALS CURE Project, to lead research towards a laser focused goal of coming up with a cure for ALS. As a 100% volunteer-based organization, we can operate this effort, without any ALS CURE Project employees. I work for ALS CURE Project gratis and expect to continue in that manner such that all funding raised will go directly towards our one goal of curing ALS from humanity.
Please click on the painting above, or the link below, to order
Jessel Miller “Gretchen with Gretchen” Acrylic
Gretchen had a special place in her heart for horses & a Clydesdale Horse was named in her honor.
Part of the proceeds of Jessel Miller Product with this image are donated to ALS CURE Project.
The ALS CURE Project was founded by Mike Piscotty and his son’s, Stephen, Nick and Austin following the passing of his wife Gretchen Piscotty on May 5, 2018.
The ALS CURE Project has one goal: rid the world of ALS so no one has to suffer Gretchen’s fate.
- Little concentrated effort by Pharma and Biotech companies to produce a drug
- Little is known about the disease.
- No biomarkers.
- Hard to create a cure for something that can’t be identified
- No new ALS drug in over 22 years since Relizolein 1995
- Only ALS drug available (upside is 10% reduction in decay rate)
- Radicava, in 2017 was a repurposed stroke drug; Questionable success
BE A PART OF THE CURE
ALS Disease Background
ALS is a horrendous disease attacking the neuromuscular system of the body, slowly and systematically rendering the person paralyzed and unable to breathe.
The journey is emotionally exhausting for family and friends as you watch your loved one wither away, becoming trapped in their bodies. As awful as this disease is and with the extraordinary medical advances giving us unprecedented views into the human body, a new drug for ALS hasn’t made it to market since 1995, leaving those with ALS and their families with little hope. ALS is classified as a rare disease with a much smaller population (20,000 US) of people affected than that of cancer (2 million US). Thus the profit potential of an ALS drug is limited and companies tend to invest where the profit potential is greatest.
Further accentuating the hopelessness is the lack of any ALS Biomarker, which is critical for drug development. There is no test for ALS. It is sadly the disease you have when you fail all the known disease tests for AIDS, MS, Parkinson’s etc. Significantly missing from our knowledge necessary to develop a cure is an understanding of the ALS disease mechanism. Knowledge of what conditions and processes trigger the start of the ALS disease and what keeps it attacking the body’s motor neurons is a critical first step to a cure.